MarketCap
Facebook
X
Telegram
Cumberland Pharmaceuticals Market Cap | CPIX
As of July 30, 2026 Cumberland Pharmaceuticals has a market cap of $ 98.9 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Cumberland Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 84.8 M | 88.6 M | 90.1 M | 32 M | 50.1 M | 47.7 M | 76.2 M | 84.9 M | 110 M | 102 M | 82.9 M | 102 M | 88.4 M | 83.5 M | 123 M | 136 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 136 M | 32 M | 86.5 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M |  USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
187 K | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
276 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
OrganiGram Holdings
OGI
|
151 M | $ 0.93 | -1.97 % | $ 88.6 M | Canada |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 10.43 | 1.26 % | $ 1.44 B | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
1.85 M | $ 1.1 | -3.51 % | $ 1.85 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Cronos Group
CRON
|
736 M | $ 2.86 | 0.35 % | $ 1.1 B | Canada |
 |
Veru
VERU
|
84.9 M | $ 2.21 | -0.9 % | $ 32.4 M | USA |
 |
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
23 M | - | 1.15 % | $ 7.11 M | USA |
 |
Canopy Growth Corporation
CGC
|
292 M | $ 0.89 | -0.53 % | $ 265 M | Canada |
 |
cbdMD
YCBD
|
3.58 M | $ 0.49 | -2.2 % | $ 1.97 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
75.4 M | - | - | $ 150 M | USA |
 |
Radius Health
RDUS
|
393 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
396 B | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
12.8 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
119 M | - | -27.8 % | $ 2.56 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | USA |
 |
Tricida
TCDA
|
408 M | - | - | $ 3.25 M | USA |
 |
Bausch Health Companies
BHC
|
2.03 B | $ 4.68 | 3.43 % | $ 1.74 B | Canada |
 |
Emergent BioSolutions
EBS
|
452 M | $ 7.35 | 0.55 % | $ 393 M | USA |
 |
China Pharma Holdings
CPHI
|
2.75 M | $ 1.2 | -8.4 % | $ 5.15 M |  China |
 |
Aurora Cannabis
ACB
|
224 M | $ 2.73 | 0.37 % | $ 150 M | Canada |
 |
Harrow Health
HROW
|
1.93 B | $ 38.68 | -1.63 % | $ 1.42 B | USA |
 |
Evolus
EOLS
|
271 M | $ 6.03 | -3.05 % | $ 389 M | USA |
 |
Rockwell Medical
RMTI
|
33.8 M | $ 6.88 | -1.57 % | $ 248 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 3.77 | 3.43 % | $ 188 M | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 8.04 | 0.88 % | $ 704 M | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 5.14 | -1.72 % | $ 203 M | USA |
 |
Organogenesis Holdings
ORGO
|
337 M | $ 2.52 | -0.4 % | $ 319 M | USA |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 26.4 | -1.53 % | $ 1.22 B | USA |
 |
TherapeuticsMD
TXMD
|
23 M | $ 2.06 | - | $ 23.8 M | USA |
 |
Sundial Growers
SNDL
|
348 M | $ 1.2 | -1.64 % | $ 310 M | Canada |
 |
Tilray
TLRY
|
3.65 B | $ 3.99 | -0.99 % | $ 3.55 B | Canada |